Vrije Universiteit Brussel (VUB) and InSphero Partner to Advance Drug Discovery for Non-Alcoholic Steatohepatitis
InSphero, leader in enabling pharma researchers to use predictive, human 3D cell-based disease models expands its NASH portfolio in collaboration with Vrije Universiteit Brussel (VUB)
Read MoreInSphero Further Strengthens Scientific Advisory Board for Liver Diseases by Appointing Professor Nikolai Naoumov
New SAB member brings rich experience and expertise in liver disease, pharma drug development as well as a keen interest in 3D in vitro technologies PDF Version Schlieren, Switzerland – […]
Read MoreInSphero Appoints Prof. Dr. Francisco Verdeguer as VP, Head of Liver Discovery Group
InSphero, the leading biotech for the development of complex 3D research disease models, announced the appointment of Prof. Francisco Verdeguer as the new Vice President, Head of the Liver Discovery Group where he will be focusing on metabolic diseases, especially NASH and associated disease models.
Read MoreInSphero to Offer Proprietary Microplates Engineered to Accelerate Development of Spheroid and Organoid Cultures
InSphero to Offer Proprietary Microplates Engineered to Accelerate Development of Spheroid and Organoid Cultures Akura™ 96- and 384-well spheroid and organoid microplates and Akura™ Plus hanging-drop plates now available […]
Read MoreInSphero and Pharmaceutical Companies Form Pre-Competitive Consortium to Advance Development of In Vitro Tools to Screen and Predict Drug-Induced Liver Injury (DILI)
InSphero and Pharmaceutical Companies Form Pre-Competitive Consortium to Advance Development of In Vitro Tools to Screen and Predict Drug-Induced Liver Injury (DILI) DILI is of significant concern to the pharmaceutical […]
Read MoreInSphero and Hamilton Announce Collaboration to Improve the Production and Handling of Spheroids Using Advanced Liquid Handling Technology
InSphero and Hamilton Announce Collaboration to Improve the Production and Handling of Spheroids Using Advanced Liquid Handling Technology Both partners have a proven track record for being a successful entrepreneur […]
Read MoreInSphero and Erasmus Medical Center Cancer Researcher Receive Grant to Develop Human In Vitro Model of Metastasis using the Akura™ Flow Technology Platform
InSphero and Erasmus Medical Center Cancer Researcher Receive Grant to Develop Human In Vitro Model of Metastasis using the Akura™ Flow Technology Platform PDF version Schlieren, Switzerland – May […]
Read MoreNovel Phenomics NASH In Vitro Assay Presented by InSphero AG and PharmaNest Inc at 2021 Society of Toxicology Meeting
Novel Phenomics NASH In Vitro Assay Presented by InSphero AG and PharmaNest Inc at 2021 Society of Toxicology Meeting Introduction of key technology to accelerate NASH drug discovery by combining […]
Read MoreInSphero CEO and Co-Founder Jan Lichtenberg Appointed to Board of Directors of the Society for Laboratory Automation and Screening (SLAS)
InSphero CEO and co-founder, Jan Lichtenberg, brings extensive experience as an entrepreneur and a technical disruptor at the intersection of 3D in vitro technologies and automation.
Read MoreInSphero and Yokogawa Enter into Partnership Agreement to Support Drug Development Research
New partnership will focus on establishing and advancing high content screening solutions using complex, physiologically relevant 3D cell-based disease models.
Read MoreInSphero Strengthens Scientific Advisory Board with Three Key Appointments to Advance Drug Discovery and Safety Solutions
New SAB members bring rich experience and expertise in human disease modeling and translational toxicology as well as a keen interest in 3D in vitro technologies.
Read MoreInSphero and ETH Zurich Bio Engineering Laboratory Achieve Milestone to Commercialize Akura™ Flow Organ-on-a-Chip Solutions
Long-term collaborative research partnership continues to serve as successful biotechnology incubator for disruptive drug discovery and safety testing platforms and applications.
Read MoreInSphero InFloat™ Microtissue Shipping System Wins Coveted Red Dot Best-of the Best Award for Product Design
Unique packaging solution, engineered to protect delicate assay-ready 3D cell-based tissue models during express shipping, captivates judges in internationally recognized competition
Read MoreInSphero Introduces Revolutionary New Transport Technology
Ingenious InFloat™ Shipping System protects and secures delicate microtissues in transit, ensuring they are ready to use in drug discovery and safety testing experiments upon arrival.
Read MoreInSphero Launches Academic Access Program for Akura™ Flow Organ-on-Chip Platform to Accelerate Biomedical Innovations
New program will enable academic research teams to develop applications for plug-and-play organ-on-chip technology without requiring resource intensive platform and model development
Read MoreInSphero Launches Online Store to Streamline Ordering Process for Researchers Heading Back the Bench as COVID-19 Shutdown Ends
Online purchasing option for assay-ready 3D InSight™ Human Liver Microtissues to help eliminate 3D model development delays for labs ready to resume compound testing and risk assessment.
Read MoreInSphero Significantly Expands Corporate Headquarters to Meet Growth in BioPharmaceutical Research Partnerships
Move optimally positions InSphero to build on its business development, scientific research, and operational teams.
Read MoreHuman Islet Microtissue Perifusion in Organ-on-a-Chip Platform Provides Diabetes Researchers a Powerful Tool for Studying Insulin Release Dynamics
New study confirms hanging drop microfluidics platform for miniaturized islet perifusion assays enables high-resolution assessment of islet insulin secretion from single human islets over time.
Read MoreInSphero offers free safety testing in 3D InSight™ Human Liver Models for exploratory COVID-19 treatments
Organizations working on new medications and vaccine formulations may request free safety testing using preclinical liver models that identify potential for toxic effects in humans.
Read MoreEnhanced production technology enables InSphero to reduce pricing of 3D InSight™ Human Liver Microtissues for broader access to assay-ready spheroid technology
New pricing structure will enable researchers to save close to 50% on 3D models for liver toxicology and drug safety testing applications
Read MoreInSphero joins Science Exchange Network to Offer Expanded Online Access to 3D InSight™ Microtissue Technology and Services
New R&D services platform will make it easier for researchers throughout the world to purchase InSphero assay ready models and services for drug efficacy and safety testing
Read MoreInSphero Wins Sino-European Innovation Award for Breakthrough NASH Discovery and Safety Testing Platform
InSphero received an award at the 2019 Sino-European Innovation Week in Healthcare Technology (SEIWHT) meeting held in Nanjing, China. At the event, InSphero highlighted its 3D InSight™ Human Liver Disease Discovery Platform for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), a breakthrough 3D cell technology for drug discovery and safety testing.
Read MoreAkero Therapeutics and InSphero partner to evaluate AKR-001 using InSphero’s 3D InSight™ Human Liver Disease platform
3D InSight™ Human Liver Disease Platform will be used to screen effects of Akero lead program AKR-001 on underlying metabolic and fibrotic drivers of NAFLD and NASH.
Read MoreInSphero and DefiniGEN Receive Eurostars Grant to Develop Human Stem Cell-derived Screening Platform for Diabetes Drug Discovery
New platform to combine stem cell and CRISPR gene-editing technology with proven 3D cell culture techniques for producing standardized pancreatic islet disease models
Read MoreInSphero human liver disease platform selected to test Cyclerion’s sGC stimulator technology as potential therapeutic approach for NASH and fibrosis
In a recent study published in the Proceedings of the National Academy of Sciences (PNAS), researchers at Cyclerion Therapeutics, a clinical stage biopharmaceutical company, used InSphero 3D InSight™ Human Liver Disease Microtissue models to evaluate praliciguat, a systemic small molecule stimulator of soluble guanylate cyclase (sGC), as a potential treatment for non-alcoholic steatohepatitis (NASH) and fibrotic liver disease. Study results support further investigation of sGC stimulation as a potential therapeutic approach for NASH and fibrosis, and validate the utility of 3D InSight™ human liver disease models for preclinical drug screening.
Read MoreJuly 17, 2019 – InSphero launches industry’s first automation-compatible 3D human liver disease platform for NASH drug discovery and screening
InSphero AG today announced a breakthrough in 3D cell technology for drug discovery and safety testing with the launch of its 3D InSight™ Human Liver Disease Discovery Platform for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The platform has been precisely engineered to include all the human liver cell types and inducers necessary to replicate progression of NASH in patients, from fatty liver (steatosis) to inflammation (NASH) and scarring (fibrosis) of the liver. This game-changing preclinical discovery platform enables scalable in vitro drug efficacy assessment, screening, combinatorial testing as well as the study of complex NASH pathophysiology.
Read MoreJune 19, 2019 – New Study Highlights Value of Physiologically Relevant 3D InSight™ Liver Microtissues for Nanomaterial Safety Assessments
Findings represent key milestone in PATROLS initiative to establish tools for evaluating health and environmental risks of nanomaterials
Read MoreFebruary 13, 2019 – InSphero Appoints Distinguished Pharma Industry Executive Prof. Armin Wolf as Chief Scientific Officer
With 30 years of cumulative experience at Novartis and Janssen, Prof. Wolf strengthens InSphero leadership team and augments 3D model and organ-on-a-chip R&D
Read MoreJanuary 31, 2019 – InSphero Organ-on-a-Chip Solutions Featured in SLAS Technology
Early proof-of-concept studies demonstrate versatility of scalable microfluidic platform for 3D microtissue-based multi-organ models.
Read MoreJanuary 24, 2019 – Registration Open for 2019 New Frontiers in 3D Conference
Exclusive one-day scientific meeting to discuss practical applications of innovative 3D-cell and organ-on-a-chip technologies to be held April 25, 2019, in Cambridge, MA
Read MoreDecember 19, 2018 – InSphero and Path BioAnalytics Announce Partnership to Develop Advanced 3D Airway Tissue Model for Cystic Fibrosis Research
Path BioAnalytics will employ InSphero 3D cell technology to produce organoids from primary cystic fibrosis patient tissues to aid in development of new treatments.
Read MoreNovember 29, 2018 – AstraZeneca Relies on 3D InSight™ Human Islet Microtissues in Pancreatic Beta-cell Study
AstraZeneca Relies on 3D InSight™ Human Islet Microtissues in Pancreatic Beta-cell Study InSphero human islet model helps reveal effects of gene silencing on pancreatic cell function using novel antisense oligonucleotide […]
Read MoreOctober 11, 2018 – InSphero achieves new milestone with Akura™ Flow organ-on-a-chip technology in low-clearance drug study
Government research project to predict hepatic clearance of drugs in humans using Akura™ Flow system results in development partnerships with top pharma companies.
Read MoreJune 13, 2018 – InSphero Receives Additional USD 10m for Organ-on-a-Chip Disease Models
Comprehensive, customizable platforms for preclinical drug safety and efficacy testing, coupled with emerging organ-on-a-chip technology, garner investor support
Read MoreJune 11, 2018 – InSphero Partners with ALPCO to Advance Diabetes Research
InSphero extends 3D InSight™ Diabetes Discovery Platform to include ALPCO STELLUX® Chemiluminescent ELISA technology for assessment of pancreatic β-cell function.
Read MoreFebruary 8, 2018 – InSphero Introduces Akura™ Flow Microphysiological System at SLAS2018
Global leader in 3D cell culture technology to deliver standardized 3D models in advanced microfluidic format ideal for organ on a chip applications.
Read MoreFebruary 1, 2018 – InSphero Joins Global Consortium Dedicated to Enhancing Safety Testing of Engineered Nanomaterials
Nanosafety experts from more than 30 institutions convene in Swansea, Wales, for PATROLS project kick off meeting.
Read MoreJanuary 3, 2018 – InSphero Certified for ISO 9001:2015
InSphero demonstrates commitment to customer satisfaction, superior quality, and continuous improvement by adhering to new ISO 9001:2015 standards.
Read MoreOctober 26, 2017 – InSphero and Charles River Announce PDX Partnership
Charles River to license PDX lines to InSphero for development of 3D InSight™ PDX Microtissues, expansion of in vitro oncology services.
Read MoreOctober 18, 2017 – InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC
InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC New 3D InSight™ Human Liver Fibrosis Model represents a powerful tool for screening efficacy […]
Read MoreJune 29, 2017 – Comprehensive Study by AstraZeneca and Genentech Confirms Superiority of InSphero Human Liver Microtissues for Prediction of Drug-Induced Liver Injury
Comprehensive Study by AstraZeneca and Genentech Confirms Superiority of InSphero Human Liver Microtissues for Prediction of Drug-Induced Liver Injury Archives of Toxicology publication reveals microtissues are twice as sensitive as […]
Read MoreJune 19, 2017 – ADA Presentations Highlight Superior Functionality of InSphero Standardized Islet Microtissues for Diabetes Drug Screening
ADA Presentations Highlight Superior Functionality of InSphero Standardized Islet Microtissues for Diabetes Drug Screening ETH Zurich researchers present single-islet study using novel microfluidic setup to display in vivo-like temporal insulin […]
Read MoreMay 03, 2017 – InSphero Announces Collaboration with NIH National Center for Advancing Translational Sciences (NCATS)
InSphero Announces Collaboration with NIH National Center for Advancing Translational Sciences (NCATS) Joint study will accelerate development of physiologically relevant 3D models for anti-cancer drug screening. PDF Version Schlieren, […]
Read MoreApril 27, 2017 – InSphero Announces Agreement with Pfizer to Develop Novel Assays for Predicting Drug-induced Liver Injury
InSphero Announces Agreement with Pfizer to Develop Novel Assays for Predicting Drug-induced Liver Injury Research effort will use InSphero 3D InSight™ Human Liver Microtissues to develop novel assays to predict […]
Read MoreApril 18, 2017 – NIH/NCATS and InSphero Host Inaugural 3D Tumor Model Standards Working Group at AACR 2017
NIH/NCATS and InSphero Host Inaugural 3D Tumor Model Standards Working Group at AACR 2017 Establishing standards for next-generation tumor models to benefit drug discovery and broader research community primary objective […]
Read MoreApril 03, 2017 – Novel 3D Cell-based Assays Accelerate Discovery for Immuno-oncology/CAR-T Therapies
Novel 3D Cell-based Assays Accelerate Discovery for Immuno-oncology/CAR-T Therapies InSphero presents latest data demonstrating immune cell interaction with 3D tumor models for in vitro efficacy testing of oncology drugs and […]
Read MoreMarch 27, 2017 – InSphero 3D Liver Microtissues Featured at Annual SOT Meeting as More Sensitive Model for DILI and Mechanistic Toxicity Testing
InSphero 3D Liver Microtissues Featured at Annual SOT Meeting as More Sensitive Model for DILI and Mechanistic Toxicity Testing Customer and company presentations highlight InSphero 3D InSight™ Liver Microtissues as [...]
Read More